Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer

Tumor Biology

Volumn 19, Issue 1, 1997, Pages 60-64

  Ray, Paul ^b   Bhatti, Rashid ^a   Gadarowski, John ^b   Bell, Nancy ^b   Nasruddin, Shahida ^b  

^a Jr Hospital of Cook County   (United States)

^b NONE

Author keywords

Amiloride; Prostatic cancer; Urokinase plasminogen activators

Indexed keywords

AMILORIDE; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; LUNG METASTASIS; LYMPH NODE METASTASIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0031469540     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000029975     Document Type: Article

References (22)

1. Fidler I: Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978;38: 2651-2660.
2. Boring C, Squires T, Tong T: Cancer statistics. 1993. CA 1993;43:7-26.
3. Dano K, Andreasen P, Grondahl J, Kristensen P, Nielsen L, Sriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:146-239.
4. Barret J, Sheela S: Plasminogen activators in metastasis; in Liotta, Hart (eds): Tumor Invasion and Metastasis. Boston, Nijhoff, 1982, p 359.
5. Keer H, Gayulis F, Kozlowski J, Kwaan H, Bauer K, Akouchi A, Sinha A, Wilson M: Heterogeneity in cellular level of expression of plasminogen activators in human prostate cancer cell lines. Invasive cells contain and secrete more UPA. Prostate 1991;18:201-204.
6. Markus G: The relevance of plasminogen activators to neoplastic growth. Enzyme 1988;40:158-172.
7. Ramshaw I, Badenoch J, Grant A, Maxted M, Claudianos C: Enhanced plasminogen activator production by highly metastatic variant cell lines of a rat mammary adenocarcinoma. Invasion Metastasis 1986;6: 133.
8. Magnati P, Rifkin D: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73: 161-195.
9. Ossowski L, Russo P, Wilson E: Inhibition of urokinase type plasminogen activator by antibodies. The effect on dissemination of a human tumor in nude mouse. Cancer Res 1991;51:274-281.
10. Wang Y, Jones C, Dang J, Liang X, Olsen J, Doe W: Human urokinase receptor expression in inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells. FEBS Lett 1994; 353:138-142.
11. Kellen J, Mirakian A, Kolin A: Antimetastatic effect of amiloride in an animal tumor model. Anticancer Res 1988;8:1373-1376.
12. Liotta L, Tryggvason K, Garbisa S, Hart I, Folty S, Shafie S: Metastatic potential correlated with enzymatic degradation of basement membrance collagen. Nature 1980,284: 67-68.
13. Jankun J, Keck RW, Jankun ES, Swiercz R: Inhibitors of urokinase reduces size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res 1997; 57:559-563.
14. Vassalli J, Belin D: Amiloride selectively inhibits the urokinase type plasmmogen activator. FEBS Lett 1987;214:187-191.
15. Hienert G, Kirchheimer J, Pfluger H, Binder B: Urokinase plasmmogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol 1988; 140:1466-1469.
16. Cubellis M, Wun T, Blasi F: Receptor mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990;9:1079-1085.
17. Bhatti R, Gadarowski J, Ray P: Metastatic behavior of prostatic tumor as influenced by the hematopoietic and hematogenous factors. Tumor Biol 1977;18:1-5.
18. Crowley C, Cohen R, Lucas B, Liu G, Shuman M, Levinson A: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993;90:5021-5025.
19. Vassalli J, Baccino D, Belin D: A cellular binding site for the M 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985;100:86-92.
20. Kirchheimer J, Pfluger H, Ritschl P, Hienert G, Binder B: Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. Invasion Metastasis 1985;5:344-355.
21. Bhatti R, Ray P, Gadarowski J, Ilkay A: The role of urokinase plasminogen activators, the hematogenous factors and the effect of transferrin in the metastatic cascade of prostatic cancer, in Rao RS, Deo MG, Sanghavi LD, Mittra I (eds): Proc Int Cancer Congr Bologna, Monduzi, 1994, pp 2205-2209.
22. Rossi M, Zetter B: Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc Natl Acad Sci USA 1992;89:6179-6201.